Comparative reactivity of remnant-like lipoprotein particles (RLP) and low-density lipoprotein (LDL) to LDL receptor and VLDL receptor: Effect of a high-dose statin on VLDL receptor expression

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 441-447

  Imagawa, Michiko ^a   Takahashi, Sadao ^a   Zenimaru, Yasuo ^a   Kimura, Tomoko ^a   Suzuki, Jinya ^a   Miyamori, Isamu ^a   Iwasaki, Tadao ^b   Hattori, Hiroaki ^b   Yamamoto, Tokuo T ^c   Nakano, Takamitsu ^d,e   Nakajima, Katsuyuki ^d,e  

^a UNIVERSITY OF FUKUI   (Japan)

^b Kawagoe shi   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

LDL; LDL receptor; RLP; Statins; VLDL receptor

Indexed keywords

APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PITAVASTATIN; REMNANT LIKE LIPOPROTEIN PARTICLE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANTIBODY AFFINITY; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOSE; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; LIPOPROTEINS, LDL; MYOBLASTS; PROTEIN BINDING; QUINOLINES; RATS; RECEPTORS, LDL; SUBSTRATE SPECIFICITY; TRANSCRIPTIONAL ACTIVATION; TRIGLYCERIDES;

ORYCTOLAGUS CUNICULUS;

EID: 84355166470     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.033     Document Type: Article

References (40)

1. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993, 223:53-71.
2. Twickler T.B., Dallinga-Thie G.M., Cohn J.S., Chapman M.J. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004, 109:1918-1925.
3. Nakajima K., Nakano T., Tokita Y., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011, 412:1306-1318.
4. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
5. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
6. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
7. Twickler T.B., Dallinga-Thie G.M., de Valk H.W., et al. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000, 20:2422-2427.
8. Dane-Stewart C.A., Watts G.F., Mamo J.C., Dimmitt S.B., Barrett P.H., Redgrave T.G. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur J Clin Invest 2001, 31:113-117.
9. de Sauvage Nolting P.R., Twickler M.B., Dallinga-Thie G.M., Buirma R.J., Hutten B.A., Kastelein J.J. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation 2002, 106:788-792.
10. Watts G.F., Cummings M.H., Umpleby M., et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995, 25:559-567.
11. Berglund L., Witztum J.L., Galeano N.F., Khouw A.S., Ginsberg H.N., Ramakrishnan R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J Lipid Res 1998, 39:913-924.
12. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 1992, 89:9252-9256.
13. Sakai J., Hoshino A., Takahashi S., et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994, 269:2173-2182.
14. Takahashi S., Sakai J., Fujino T., et al. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb 2004, 11:200-208.
15. Takahashi S., Suzuki J., Kohno M., et al. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 1995, 270:15747-15754.
16. Takahashi S., Oida K., Ookubo M., et al. Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3. FEBS Lett 1996, 386:197-200.
17. Kosaka S., Takahashi S., Masamura K., et al. Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages. Circulation 2001, 103:1142-1147.
18. Takahashi S., Ito T., Zenimaru Y., et al. Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expression. Biochem Biophys Res Commun 2011, 407:656-662.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
20. Zenimaru Y., Takahashi S., Takahashi M., et al. Glucose deprivation accelerates VLDL receptor-mediated TG-rich lipoprotein uptake by AMPK activation in skeletal muscle cells. Biochem Biophys Res Commun 2008, 368:716-722.
21. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
22. Iwasaki T., Takahashi S., Takahashi M., et al. Deficiency of the very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor. Endocrinology 2005, 146:3286-3294.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
24. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
25. Kugiyama K., Doi H., Takazoe K., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99:2858-2860.
26. Lundman P., Eriksson M., Schenck-Gustafsson K., Karpe F., Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997, 96:3266-3268.
27. Vogel R.A., Corretti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997, 79:350-354.
28. Kugiyama K., Doi H., Motoyama T., et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998, 97:2519-2526.
29. Doi H., Kugiyama K., Oka H., et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000, 102:670-676.
30. Kita T., Brown M.S., Bilheimer D.W., Goldstein J.L. Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci U S A 1982, 79:5693-5697.
31. Aguilar-Salinas C.A., Barrett H., Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 1998, 141:203-207.
32. Kobayashi K., Oka K., Forte T., et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. Biochem Biophys Res Commun 1996, 271:6852-6860.
33. Kozarsky K.F., Jooss K., Donahee M., Strauss J.F., Wilson J.M. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996, 13:54-62.
34. Brown M.S., Goldstein J.L. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009, 50:S15-S27. Suppl.
35. Tao H., Aakula S., Abumrad N.N., Hajri T. Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. Am J Physiol Endocrinol Metab 2010, 298:E68-E79.
36. Hong C., Duit S., Jalonen P., et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem 2010, 285:19720-19726.
37. Ishigami M., Yamashita S., Sakai N., et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 2003, 168:359-366.
38. Kawashiri M.A., Kobayashi J., Nohara A., et al. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin Chim Acta 2011, 412:1068-1075.
39. Kobayashi J., Maruyama T., Masuda M., Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta 2001, 314:261-264.
40. Schneider W.J., Kovanen P.T., Brown M.S., et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981, 68:1075-1085.